Recurrent respiratory papillomatosis: Analysis of the economic impact generated by surgical treatment
DOI:
https://doi.org/10.24265/horizmed.2017.v17n4.06Keywords:
Recurrent respiratory papillomatosis, Treatment, CostAbstract
Objective: To evaluate the economic impact generated by surgical treatment of recurrent respiratory papillomatosis in the tertiary care level. Recurrent respiratory papillomatosis is a prevalent entity. The economic impact it generates is mainly due to the need for repeated surgical interventions throughout its progression, in addition to the morbidity it causes to the patient. Materials and methods: This retrospective, observational, cross-sectional study was carried out at the Specialty Hospital No. 2, National Medical Center of the Northwest, Mexican Social Security Institute (IMSS), using a non-probability sampling by consecutive case series. In the general description of the study, clinical records of patients diagnosed with recurrent respiratory papillomatosis treated at this institution from January 2010 to January 2012 were reviewed. Data such as age, gender, surgical management and/or adjuvant therapy, and cost generated by exclusive surgical care, were collected. Results: Out of a total of 103 reviewed files, only 39 were complete and met the inclusion criteria: 16 (41%) were female and 23 (59%) were male. Twenty-seven (27) cases (69%) were juvenile patients and 12 (30.8%) were adults. Only 19 cases (48.7%) received adjuvant therapy. Tracheotomy was performed in 15 cases (38.5%). The direct cost for resection surgery was $322,943.92 (22,190 USD) in the juvenile group and $55,225.33 (3,790 USD) in the adult group. Conclusions: Surgical treatment for recurrent respiratory papillomatosis represents a financial burden and great morbidity for both health institutions and the family.
Downloads
References
Hadha NK, James AL. Tratamiento antiviral adyuvante para la papilomatosis respiratoria recurrente . En: La Biblioteca Cochrane Plus, 2008 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com
Derkay CS, Malis DJ, Zalzal G, Wiatrak BJ, Kashima HK, Coltrera MD.A staging system for assessing severity of disease and response to therapyin recurrent respiratory papillomatosis. Laryngoscope 1998;108(6):935-7.
Kimberlin DW. Current status of antiviral therapy for juvenileonset recurrent respiratory papillomatosis. Antiviral Research 2004;63(3):141-51.
Shykhon M, Kuo M, Pearman K. Recurrent respiratory papillomatosis. Clinical Otolaryngology and Allied Sciences. 2002;27:237-43.
Menzo S, Monachetti A, Trozzi C, Ciavattini A, Carloni G, Varaldo PE, et al. Identification of six putative novel human papillomaviruses (HPV) and characterization of candidate HPV type 87. Journal of Virology 2001;75(23):11913 9.,
Rabah R, Lancaster W, Thomas R, Gregoire L. Human papillomavirus-11-associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus- 6-associated disease. Pediatric and Developmental Pathology. 2001;4(1):68-72.
Silverberg M, Thorsen P, Lindeberg H, Grant L, Shah K. Condyloma in pregnancy is strongly predictive of juvenileonset recurrent respiratory papillomatosis. Obstetrics and Gynecol 2003;101(4):645-52.
Kashima H, Shah F, Lyles A, Glackin R, Muhammad N, Turner L, et al. A comparison of risk factors in juvenile-onset and adultonset recurrent respiratory papillomatosis. Laryngoscope. 1992;102(1):9-13.
Derkay C. Recurrent respiratory papillomatosis. Laryngoscope. 2001;111:57-69
Mehta D. British National Formulary. 46th Edition. British Medical Association and Royal Pharmaceutical Society of Great Britain, 2003.
Schraff S, Derkay S, Burke B, Lawson L. American Society of Pediatric Otolaryngology members’ experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg. 2004;130(9):1039-42.
Derkay C, Wiatrak B. Recurrent Respiratory Papillomatosis: A Review, Laryngoscope, 2008;118:1236 –47
Bishai D, Kashima H, Shah K. The cost of juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 2009;135(2):208.
Derkay C. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg. 1995;121(12):1386-91.
Graupp M, Gugatschka M, Kiesler K, Reckenzaun E, Hammer G, Friedrich G. Experience of 11 years use of cidofovir in recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2013;270(2):641-6.
Shapiro A. Tracheotomy in children with juvenile-onset recurrent respiratory papillomatosis: the Children’s Hospital of Pittsburgh experience. Ann Otol Rhinol Laryngol. 1996;105(1):1-5
Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol. 2008;198(5):.e1-e7.
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
